PAX8 is expressed in pancreatic well‐differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine‐needle aspiration biopsy specimens
Authors:
Open Access
- 15 February 2011
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 119 (3) , 193-201
Abstract
BACKGROUND: PAX (paired box) genes encode a family of transcription factors important for organogenesis. Recently, PAX8 has been recognized as a potential immunohistochemical marker of pancreatic neuroendocrine tumors. The authors evaluated PAX8 expression in fine‐needle aspiration biopsies of neuroendocrine tumors to establish whether PAX8 immunohistochemistry can be used as an ancillary marker of pancreatic origin for neuroendocrine tumors.METHODS: Fine‐needle aspiration biopsies from 72 neuroendocrine tumors were evaluated for PAX8 expression: 32 primary and 23 metastatic well‐differentiated neuroendocrine tumors (25 pancreatic, 13 pulmonary, 3 ileal, 2 duodenal, 1 rectal, 1 ovarian, and 10 primary site unknown) and 17 poorly differentiated neuroendocrine carcinomas (11 pulmonary, 1 pancreas, 1 breast, 1 thymus, and 3 primary site unknown).RESULTS: Among well‐differentiated neuroendocrine tumors, only tumors from the pancreas were PAX8 positive (14 of 25, 56%) whereas no cases of pulmonary (0 of 13), ileal (0 of 3), duodenal (0 of 2), rectal (0 of 1), or ovarian (0 of 1) well‐differentiated neuroendocrine tumors were positive for PAX8. One of 10 (10%) well‐differentiated neuroendocrine tumors of unknown primary origin was PAX8 positive. Among poorly differentiated neuroendocrine carcinomas, PAX8 expression was identified in 1 of 1 (100%) pancreatic, 1 of 1 (100%) thymic, 4 of 11 (36%) pulmonary, and 0 of 1 (0%) breast carcinomas. One of 3 (33%) poorly differentiated neuroendocrine carcinomas of unknown primary origin was PAX8 positive.CONCLUSIONS: Pancreatic well‐differentiated neuroendocrine tumors frequently express PAX8, which can help distinguish pancreatic primary tumors from tumors of other anatomic sites. In contrast, PAX8 expression in poorly differentiated neuroendocrine carcinomas is not specific for pancreatic origin and can be seen in extrapancreatic poorly differentiated neuroendocrine carcinomas. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer SocietyKeywords
This publication has 32 references indexed in Scilit:
- PAX8 Expression in Well-differentiated Pancreatic Endocrine Tumors: Correlation With Clinicopathologic Features and Comparison With Gastrointestinal and Pulmonary Carcinoid TumorsAmerican Journal of Surgical Pathology, 2010
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Thyroid transcription factor-1 expression in ovarian epithelial neoplasmsLaboratory Investigation, 2008
- Neuroendocrine tumors of the diffuse neuroendocrine systemCurrent Opinion in Oncology, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Review of endoscopic ultrasound‐guided fine‐needle aspiration cytologyDiagnostic Cytopathology, 2006
- Usefulness of CDX2 and TTF-1 in Differentiating Gastrointestinal From Pulmonary CarcinoidsAmerican Journal of Clinical Pathology, 2005
- Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral CenterAnnals of the New York Academy of Sciences, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003